Key facts
- FenoMark Diagnostics’s last known valuation is $4.7M (Dec 2025).
- It has raised $2.0M.
- Notable investors include Almi Invest, AN Business Framework, Blue Cabinet, DRIVE ( KI Innovations Business Incubator), Karolinska Institutet Holding — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for FenoMark Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for FenoMark Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FenoMark Diagnostics
Developer of proteomics-based diagnostic technology designed to enable precise clinical analysis of patient samples. The company's platform offers standardized workflows, mass spectrometry-based proteomics, and integrated data analysis and reporting tools, enabling medical professionals to generate actionable clinical insights and improve patient-specific decision-making.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2019
- Employees
- 5
- Website
- fenomark.com/
- Ownership
- Privately Held (backing)
FenoMark Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FenoMark Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FenoMark Diagnostics in its N-PORT filings yet. We sweep new filings monthly.